Heron Therapeutics vs Arcus Biosciences
HRTX and RCUS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HRTX and RCUS compare
Arcus Biosciences is the larger company, worth 38 times as much as Heron Therapeutics ($2.2B against $58.9M).
Heron Therapeutics grew revenue faster over the last twelve months (−4.4% versus −58.3% for Arcus Biosciences).
Heron Therapeutics keeps more of each dollar of sales as profit, with a net margin of −14.5% compared with −453% at Arcus Biosciences.
Heron Therapeutics scores higher on the StockData Score (8 against 3 for Arcus Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HRTX | RCUS |
|---|---|---|
| Size and price | ||
| Market cap | $58.9M | $2.2B |
| Share price | $0.310 | $17.43 |
| Change, 1 year | −72.0% | −12.8% |
| Change, 5 years | −96.9% | −63.3% |
| Beta (5Y) | 1.79 | 1.42 |
| Employees | 128 | 601 |
| StockData Score | ||
| Total score | 8 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 2 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.4× (better) | 22.2× |
| P/B | 12.0× | 6.2× (better) |
| FCF yield | −24.4% | −21.0% (better) |
| Fair value | – | $5.80 |
| Margin of safety | – | −201% |
| Growth | ||
| Revenue growth (TTM) | −4.4% (better) | −58.3% |
| Revenue growth, 5Y average | 11.8% | 25.9% (better) |
| Profitability | ||
| Gross margin | 71.5% | – |
| Operating margin | −5.7% (better) | −475% |
| Net margin | −14.5% (better) | −453% |
| FCF margin | −9.7% (better) | −466% |
| Return on equity | −218% | −114% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −43.2× |
| Current ratio | 2.33 | 3.34 (better) |
| Altman Z-score | −10.60 | −1.35 (better) |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −12.6% |
| Shareholder yield | 0.00% (better) | −12.6% |
| Ownership | ||
| Held by institutions | 70.4% | 96.3% |
| Held by insiders | 21.6% | 31.7% |
| Insider net buying, 12 months | – | −$9.3M |
| Short interest, % of float | 22.8% | 15.2% |
Go deeper
- HRTX stock overview
- HRTX income statement
- HRTX valuation and score
- RCUS stock overview
- RCUS income statement
- RCUS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.